Aragen Life Sciences Ltd.
NSE & BSETBA
TBA
1 Shares
TBA
₹10
Financial Summary
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| 21,783.92 | 18,451.07 | |
| 471.96 | 251.85 | |
| 22,255.88 | 18,702.92 | |
| 16,185.87 | 13,899.87 | |
| 3,560.48 | 2,563.69 | |
| 2,576.44 | 1,803.8 |
Subscription Details
IPO Timeline
IPO Offer Start
TBA
IPO Offer Ends
TBA
TBA
Use of Proceeds
| # | Purpose | Amount (₹ Million) |
|---|---|---|
| 1 | Repayment and/or pre-payment, in part or full of certain borrowings availed by our Company and | 3,850 |
| 2 | Capital expenditure to be incurred by the Company for purchase of new equipment and machinery | 1,540 |
| 3 | Capital expenditure to be incurred by one of our Material Subsidiaries, namely Aragen Biologics | 710 |
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
59.44%
Promoter stake
IPO Registrar
KFIN Technologies Ltd.
About the Company
We are a fully integrated contract research, development and manufacturing organization (“CRDMO”) serving global innovator companies and emerging firms in the life sciences industry. We offer comprehensive solutions across the entire drug development lifecycle spanning contract discovery and pre-clinical research solutions (“CRO” or “Contract Research”) and contract development and manufacturing solutions (“CDMO”) for both small molecules and biologics. With more than 25 years of operations, we have become the largest CRDMO among the assessed Indian peers in terms of number of solutions offered across the drug development value chain as of March 31, 2026 (Source: F&S Report). We have become one of the top three largest Indian CRDMOs in terms of operating revenue among the assessed Indian peers, operating in a global CRDMO market estimated at USD 171 billion in Fiscal 2026 (Source: F&S Report). Our platform focuses on life sciences companies that are engaged in new chemical entities (“NCEs”) and new biological entities (“NBEs”) and we served as a strategic partner to 591 customers globally in Fiscal 2026, across key markets including the United States, Europe, Japan, India and other APAC markets. Our customer base comprises Big Pharma companies, large pharmaceutical companies, small / biotechnology companies and mid-sized pharmaceutical companies operating across pharmaceuticals, biotechnology, animal health, agrochemicals and specialty chemicals. We worked with 16 of the Top 20 Big Pharma customers as of March 31, 2026 (Source: F&S Report). We also recorded the second highest revenue from operations growth between Fiscal 2025 and Fiscal 2026 among the assessed Indian peers, according to the F&S Report.
Use of Proceeds
1.Repayment and/or pre-payment, in part or full, of certain borrowings availed by our Company and our Material Subsidiaries; 2.Capital expenditure to be incurred by the Company for purchase of new equipment and machinery for the facilities in Hyderabad; 3.Capital expenditure to be incurred by one of our Material Subsidiaries, namely, Aragen Biologics Private Limited for the facility in Bengaluru towards purchase of new equipment and machinery for the following: a.Expansion of biologics drug substance capacity (“Drug Substance Expansion”); and b.Establishment of biologics drug product fill and finish capability (“Fill and Finish Line Establishment”); and 4.General corporate purposes
Aragen Life Sciences Ltd. Latest News
IPO FAQs
The for the Aragen Life Sciences Ltd. IPO is 1 shares, which is also the minimum order quantity — you have to apply for at least 1 shares, and in multiples of 1 beyond that.
KFIN Technologies Ltd. is the for the Aragen Life Sciences Ltd. IPO.
The registrar processes the , refunds and the credit of shares to your demat account, so allotment-status queries go to them.
Aragen Life Sciences Ltd. IPO shares are proposed to be listed on BSE and NSE.
Each Aragen Life Sciences Ltd. share has a of ₹10.
Face value is the nominal value recorded in the company's books and is separate from the issue price you pay.
held 59.44% of Aragen Life Sciences Ltd. before the IPO.
- 1.Repayment and/or pre-payment, in part or full, of certain borrowings availed by our Company and our Material Subsidiaries
- 2.Capital expenditure to be incurred by the Company for purchase of new equipment and machinery for the facilities in Hyderabad
- 3.Capital expenditure to be incurred by one of our Material Subsidiaries, namely, Aragen Biologics Private Limited for the facility in Bengaluru towards purchase of new equipment and machinery for the following: a.Expansion of biologics drug substance capacity (“Drug Substance Expansion”); and b.Establishment of biologics drug product fill and finish capability (“Fill and Finish Line Establishment”)
- 4.General corporate purposes
Axis Capital Ltd., Citigroup Global Markets India Pvt Ltd., Goldman Sachs (India) Securities Pvt Ltd and JM Financial Consultants Pvt Ltd are the for the Aragen Life Sciences Ltd. IPO.
Pre-apply means placing your Aragen Life Sciences Ltd. application before the subscription window actually opens. The bid is held and forwarded to the exchange on the opening day, so you don't have to submit it in the rush of the first morning.
Applying early doesn't improve your chances — when an issue is oversubscribed, the for investors is decided by a lottery, not by who applied first. Your money is only blocked once the application reaches the exchange.
You can apply in the Aragen Life Sciences Ltd. IPO online using either UPI or ASBA as the payment method. ASBA applications are made through the net banking of a bank account that supports IPO applications — the bank blocks the amount in your account instead of debiting it. UPI applications are offered by brokers that don't provide banking services: you enter your UPI ID and then approve the mandate request in your UPI app.
Either route needs a demat account. You bid for at least one lot, at a price within the or at the cut-off price, and the money stays blocked in your bank account until the is finalised.
Your broker or bank confirms the bid once it has been submitted to the exchange, usually within a few minutes during the bidding window. A UPI application only goes live after you approve the mandate request — ignore it and the bid lapses, even though it looks placed.
You can check the Aragen Life Sciences Ltd. bid independently on the NSE or BSE IPO bid-verification page a day after applying. An ASBA application also shows up as a blocked amount in your bank statement.